BackgroundThe recommendations in guidelines are based on evidence; however, there is a
gap between recommendations and clinical practice.ObjectiveTo describe the practice of prescribing evidence-based treatments for
patients with acute coronary syndrome in Brazil.MethodsThis study carried out a subanalysis of the ACCEPT registry, assessing
epidemiological data and the prescription rate of acetylsalicylic acid,
p2y12 inhibitors, antithrombotic drugs, beta-blockers,
angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers
(IAT1RB), and statins. In addition, the quality of myocardial reperfusion in
ST-segment elevation myocardial infarction was evaluated.ResultsThis study assessed 2,453 patients. The prescription rates of acetylsalicylic
acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers,
angiotensin-converting enzyme inhibitors/IAT1RB, and statins were as
follows: in 24 hours - 97.6%, 89.5%, 89.1%, 80.2%, 67.9% and 90.6%; and at
six months - 89.3%, 53.6%, 0%, 74.4%, 57.6% and 85.4%, respectively.
Regarding ST-segment elevation myocardial infarction, only 35.9% and 25.3%
of the patients underwent primary angioplasty and thrombolysis,
respectively, within the recommended times.ConclusionThis registry showed high initial prescription rates of antiplatelet drugs,
antithrombotic drugs, and statins, and lower prescription rates of
beta-blockers and angiotensin-converting enzyme inhibitors/IAT1RB.
Independently of the class, the use of all drugs decreased by six months.
Most patients with ST-segment elevation myocardial infarction did not
undergo myocardial reperfusion within the time recommended.
